Sharps Technology Secures SC Asset Purchase Exclusivity With $1M Escrow Deposit For The Exclusive Rights To Purchase The InjectEZ Assets From Nephron Pharmaceuticals In West Columbia, South Carolina
Portfolio Pulse from Benzinga Newsdesk
Sharps Technology has secured exclusivity to purchase InjectEZ assets from Nephron Pharmaceuticals with a $1 million escrow deposit. The acquisition will establish Sharps' position in the prefillable syringe industry, with product orders totaling over $200 million expected in the first five years. Shipments are planned to begin by Q2 2025.
June 05, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sharps Technology has secured exclusivity to purchase InjectEZ assets from Nephron Pharmaceuticals with a $1 million escrow deposit. This acquisition will establish Sharps' position in the prefillable syringe industry, with product orders totaling over $200 million expected in the first five years. Shipments are planned to begin by Q2 2025.
The acquisition of InjectEZ assets positions Sharps Technology strongly in the prefillable syringe market, with significant revenue potential from $200 million in product orders over five years. The exclusivity and escrow deposit indicate a high likelihood of the deal closing, which is expected to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100